A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer.
Forbes
C
C
NHS Centre for Reviews and Dissemination, University of York, UK.
Wilby
J
J
Richardson
G
G
Sculpher
M
M
Mather
L
L
Riemsma
R
R
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004317:Doxorubicin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013222:State Medicine; D013534:Survival; D006113:United Kingdom
D000970:Antineoplastic Agents; D004317:Doxorubicin